# Tirzepatide dosage & reconstitution (10 mg vial)

Tirzepatide dosage: calculations for a 10 mg vial use the same amounts described in the literature. Adding 2 mL of bacteriostatic water produces 5 mg/mL, so each U-100 unit contains 50 mcg.

- **Vial contents:** 10 mg Tirzepatide
- **Final volume:** 2 mL
- **Concentration:** 5 mg/mL
- **One U-100 unit:** 50 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing

### Standard Weekly Escalation Schedule (2 mL = ~5 mg/mL)

| Study phase | Weekly dose | Units per injection (mL) |
|---|---|---|
| Weeks 1 to 4 | 2.5 mg (2500 mcg) | 50 units (0.50 mL) |
| Weeks 5 to 8 | 5 mg (5000 mcg) | 100 units (1.00 mL) |
| Weeks 9 to 12 | 7.5 mg (7500 mcg) | Split: 2 × 75 units (0.75 mL each) |
| Weeks 13 to 16 | 10 mg (10000 mcg) | Split: 2 × 100 units (1.00 mL each) |
| Weeks 17 to 20 | 12.5 mg (12500 mcg) | Split: 3 × 83.3 units (0.83 mL each) |
| Weeks 21+ | 15 mg (15000 mcg) | Split: 3 × 100 units (1.00 mL each) |

Frequency: Once weekly, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 2 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 100 injections |
| 5 | 0.05 mL | 250 mcg | 40 injections |
| 10 | 0.10 mL | 500 mcg | 20 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 10 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 6 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 4 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 2 injections |

## Supplies Needed

**Tirzepatide vials (10 mg each)**
- Standard Weekly Escalation Schedule, 12 weeks: Minimum 6 vials (60 mg required).
- Standard Weekly Escalation Schedule, 24 weeks: Minimum 21 vials (210 mg required).

**U-100 syringes (1 mL)**
- Standard Weekly Escalation Schedule, 12 weeks: 16 new syringes for 12 injections.
- Standard Weekly Escalation Schedule, 24 weeks: 48 new syringes for 24 injections.

**Bacteriostatic water**
- Standard Weekly Escalation Schedule, 12 weeks: 12 mL total (2 mL per vial) → 4 × 3 mL vials.
- Standard Weekly Escalation Schedule, 24 weeks: 42 mL total (2 mL per vial) → 14 × 3 mL vials.

**Alcohol swabs**
- Standard Weekly Escalation Schedule, 12 weeks: 32 minimum; one box of 100 covers the calculation.
- Standard Weekly Escalation Schedule, 24 weeks: 96 minimum; one box of 100 covers the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

Tirzepatide simultaneously activates two incretin pathways that normally operate in a coordinated manner in post-prandial physiology: GLP-1 Pathway: Increases glucose-dependent insulin secretion from pancreatic beta cells Suppresses glucagon secretion from alpha cells Delays gastric emptying, prolonging post-meal satiety Acts on hypothalamic nuclei (arcuate, paraventricular) modulating appetite GIP Pathway: Potentiates GLP-1-induced insulin secretion Modulates lipid metabolism in adipose tissue Improves nutrient partitioning toward oxidation vs storage Reduces low-grade inflammation in visceral adipose tissue The combination produces a documented synergistic effect: simultaneous activation of both receptors generates a greater metabolic response than the sum of each component separately, especially in terms of fat mass loss with relative preservation of lean mass.

## References

1. Jastreboff AM et al. N Engl J Med 2022;387(3):205-216. PMID 35658024
2. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3-14.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.
5. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155.
6. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205.

---
Source: https://protocolopeptidos.com/en/compuestos/tirzepatide-10mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.